source
- AdvanCell secures $315M Series D to advance lead-based prostate cancer therapyAdvanCell announced a $315 million Series D financing round aimed at supporting development of its lead-based prostate cancer agent and expanding U.S. manufacturing capacity for the radioactive tre…
- Agentic AI poised to reshape clinical development by moving beyond tools to autonomous decision-makingEarlier this year, a colleague argued that clinical leaders should stop asking whether they have an 'AI strategy', because the question often leads to the wrong conversation. Instead, leaders are…